Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $20.75.

A number of brokerages recently issued reports on ZVRA. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, HC Wainwright increased their price target on shares of Zevra Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 5th.

Zevra Therapeutics Price Performance

Shares of ZVRA stock traded up $0.33 on Wednesday, reaching $7.86. The company had a trading volume of 797,506 shares, compared to its average volume of 440,358. The business’s 50-day moving average is $6.91 and its 200 day moving average is $5.67. The stock has a market capitalization of $328.96 million, a PE ratio of -5.82 and a beta of 1.94. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.44. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same period in the prior year, the company posted ($0.15) EPS. Equities research analysts forecast that Zevra Therapeutics will post -1.58 EPS for the current fiscal year.

Insider Activity

In related news, Director Thomas Anderson bought 10,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were bought at an average price of $6.81 per share, with a total value of $68,100.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $136,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 22,000 shares of company stock worth $140,340 over the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Jump Financial LLC purchased a new stake in Zevra Therapeutics in the 4th quarter valued at about $217,000. Janney Montgomery Scott LLC lifted its stake in Zevra Therapeutics by 1.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after buying an additional 9,062 shares during the last quarter. Focus Financial Network Inc. ADV acquired a new position in shares of Zevra Therapeutics during the fourth quarter worth approximately $141,000. Armistice Capital LLC bought a new position in shares of Zevra Therapeutics in the fourth quarter worth $1,755,000. Finally, Virtu Financial LLC bought a new position in Zevra Therapeutics in the 4th quarter valued at about $177,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.